In the scholarly study, Zetia failed to shrink buildups in artery wall space while a rival drug, Niaspan, did so significantly. Zetia users also experienced more heart attacks and other problems although the amounts of these events were as well small to draw firm conclusions. Zetia ‘has been available for about seven years and we still haven’t established that it improves scientific outcomes,’ stated Dr. Roger Blumenthal, preventive cardiology chief at Johns Hopkins University. The new results will be ‘very influential’ in getting ultimately more doctors to turn to Niaspan, he stated. He wrote an editorial accompanying the results, which were shown Sunday at an American Heart Association conference and published on the Internet by the New England Journal of Medication.Other research results included: 29.2 % of black sufferers received glycoprotein IIb/IIIa inhibitors within a day in comparison to 35.7 % of white patients. 32.1 % of dark individuals received clopidogrel within a day in comparison to 40.6 % of white patients. 36.3 % of black individuals received cardiac catheterization within 48 hours of hospitalization in comparison to 49 % of white individuals. 17.5 % of black patients received angioplasty within 48 hours, while 29.3 % of white individuals had the task within 48 hours. 8.1 % of black sufferers underwent coronary bypass surgery, in comparison to 12.1 % of white individuals.